Modeling drug resistance in a conjoint normal-tumor setting
Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: n...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Feizabadi, Mitra Shojania [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Shojania Feizabadi and Witten; licensee BioMed Central. 2015 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Theoretical biology and medical modelling - London : BioMed Central, 2004, 12(2015), 1 vom: 15. Jan. |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2015 ; number:1 ; day:15 ; month:01 |
| Links: |
|---|
| DOI / URN: |
10.1186/1742-4682-12-3 |
|---|
| Katalog-ID: |
SPR029130530 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR029130530 | ||
| 003 | DE-627 | ||
| 005 | 20230519175431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1742-4682-12-3 |2 doi | |
| 035 | |a (DE-627)SPR029130530 | ||
| 035 | |a (SPR)1742-4682-12-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feizabadi, Mitra Shojania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modeling drug resistance in a conjoint normal-tumor setting |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 | ||
| 520 | |a Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. | ||
| 650 | 4 | |a Cancer modeling |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cellular aging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Conjoint cell growth |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug resistance |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Witten, Tarynn M |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Theoretical biology and medical modelling |d London : BioMed Central, 2004 |g 12(2015), 1 vom: 15. Jan. |w (DE-627)39178482X |w (DE-600)2156462-0 |x 1742-4682 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2015 |g number:1 |g day:15 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/1742-4682-12-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2015 |e 1 |b 15 |c 01 | ||
| author_variant |
m s f ms msf t m w tm tmw |
|---|---|
| matchkey_str |
article:17424682:2015----::oeigrgeitnencnonnr |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1186/1742-4682-12-3 doi (DE-627)SPR029130530 (SPR)1742-4682-12-3-e DE-627 ger DE-627 rakwb eng Feizabadi, Mitra Shojania verfasserin aut Modeling drug resistance in a conjoint normal-tumor setting 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 Witten, Tarynn M aut Enthalten in Theoretical biology and medical modelling London : BioMed Central, 2004 12(2015), 1 vom: 15. Jan. (DE-627)39178482X (DE-600)2156462-0 1742-4682 nnns volume:12 year:2015 number:1 day:15 month:01 https://dx.doi.org/10.1186/1742-4682-12-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2015 1 15 01 |
| spelling |
10.1186/1742-4682-12-3 doi (DE-627)SPR029130530 (SPR)1742-4682-12-3-e DE-627 ger DE-627 rakwb eng Feizabadi, Mitra Shojania verfasserin aut Modeling drug resistance in a conjoint normal-tumor setting 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 Witten, Tarynn M aut Enthalten in Theoretical biology and medical modelling London : BioMed Central, 2004 12(2015), 1 vom: 15. Jan. (DE-627)39178482X (DE-600)2156462-0 1742-4682 nnns volume:12 year:2015 number:1 day:15 month:01 https://dx.doi.org/10.1186/1742-4682-12-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2015 1 15 01 |
| allfields_unstemmed |
10.1186/1742-4682-12-3 doi (DE-627)SPR029130530 (SPR)1742-4682-12-3-e DE-627 ger DE-627 rakwb eng Feizabadi, Mitra Shojania verfasserin aut Modeling drug resistance in a conjoint normal-tumor setting 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 Witten, Tarynn M aut Enthalten in Theoretical biology and medical modelling London : BioMed Central, 2004 12(2015), 1 vom: 15. Jan. (DE-627)39178482X (DE-600)2156462-0 1742-4682 nnns volume:12 year:2015 number:1 day:15 month:01 https://dx.doi.org/10.1186/1742-4682-12-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2015 1 15 01 |
| allfieldsGer |
10.1186/1742-4682-12-3 doi (DE-627)SPR029130530 (SPR)1742-4682-12-3-e DE-627 ger DE-627 rakwb eng Feizabadi, Mitra Shojania verfasserin aut Modeling drug resistance in a conjoint normal-tumor setting 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 Witten, Tarynn M aut Enthalten in Theoretical biology and medical modelling London : BioMed Central, 2004 12(2015), 1 vom: 15. Jan. (DE-627)39178482X (DE-600)2156462-0 1742-4682 nnns volume:12 year:2015 number:1 day:15 month:01 https://dx.doi.org/10.1186/1742-4682-12-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2015 1 15 01 |
| allfieldsSound |
10.1186/1742-4682-12-3 doi (DE-627)SPR029130530 (SPR)1742-4682-12-3-e DE-627 ger DE-627 rakwb eng Feizabadi, Mitra Shojania verfasserin aut Modeling drug resistance in a conjoint normal-tumor setting 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 Witten, Tarynn M aut Enthalten in Theoretical biology and medical modelling London : BioMed Central, 2004 12(2015), 1 vom: 15. Jan. (DE-627)39178482X (DE-600)2156462-0 1742-4682 nnns volume:12 year:2015 number:1 day:15 month:01 https://dx.doi.org/10.1186/1742-4682-12-3 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2015 1 15 01 |
| language |
English |
| source |
Enthalten in Theoretical biology and medical modelling 12(2015), 1 vom: 15. Jan. volume:12 year:2015 number:1 day:15 month:01 |
| sourceStr |
Enthalten in Theoretical biology and medical modelling 12(2015), 1 vom: 15. Jan. volume:12 year:2015 number:1 day:15 month:01 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Cancer modeling Cellular aging Conjoint cell growth Chemotherapy Drug resistance |
| isfreeaccess_bool |
true |
| container_title |
Theoretical biology and medical modelling |
| authorswithroles_txt_mv |
Feizabadi, Mitra Shojania @@aut@@ Witten, Tarynn M @@aut@@ |
| publishDateDaySort_date |
2015-01-15T00:00:00Z |
| hierarchy_top_id |
39178482X |
| id |
SPR029130530 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029130530</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519175431.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1742-4682-12-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029130530</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1742-4682-12-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Feizabadi, Mitra Shojania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Modeling drug resistance in a conjoint normal-tumor setting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Shojania Feizabadi and Witten; licensee BioMed Central. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer modeling</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cellular aging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conjoint cell growth</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug resistance</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witten, Tarynn M</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Theoretical biology and medical modelling</subfield><subfield code="d">London : BioMed Central, 2004</subfield><subfield code="g">12(2015), 1 vom: 15. Jan.</subfield><subfield code="w">(DE-627)39178482X</subfield><subfield code="w">(DE-600)2156462-0</subfield><subfield code="x">1742-4682</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:01</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1742-4682-12-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">01</subfield></datafield></record></collection>
|
| author |
Feizabadi, Mitra Shojania |
| spellingShingle |
Feizabadi, Mitra Shojania misc Cancer modeling misc Cellular aging misc Conjoint cell growth misc Chemotherapy misc Drug resistance Modeling drug resistance in a conjoint normal-tumor setting |
| authorStr |
Feizabadi, Mitra Shojania |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)39178482X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1742-4682 |
| topic_title |
Modeling drug resistance in a conjoint normal-tumor setting Cancer modeling (dpeaa)DE-He213 Cellular aging (dpeaa)DE-He213 Conjoint cell growth (dpeaa)DE-He213 Chemotherapy (dpeaa)DE-He213 Drug resistance (dpeaa)DE-He213 |
| topic |
misc Cancer modeling misc Cellular aging misc Conjoint cell growth misc Chemotherapy misc Drug resistance |
| topic_unstemmed |
misc Cancer modeling misc Cellular aging misc Conjoint cell growth misc Chemotherapy misc Drug resistance |
| topic_browse |
misc Cancer modeling misc Cellular aging misc Conjoint cell growth misc Chemotherapy misc Drug resistance |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Theoretical biology and medical modelling |
| hierarchy_parent_id |
39178482X |
| hierarchy_top_title |
Theoretical biology and medical modelling |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)39178482X (DE-600)2156462-0 |
| title |
Modeling drug resistance in a conjoint normal-tumor setting |
| ctrlnum |
(DE-627)SPR029130530 (SPR)1742-4682-12-3-e |
| title_full |
Modeling drug resistance in a conjoint normal-tumor setting |
| author_sort |
Feizabadi, Mitra Shojania |
| journal |
Theoretical biology and medical modelling |
| journalStr |
Theoretical biology and medical modelling |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| author_browse |
Feizabadi, Mitra Shojania Witten, Tarynn M |
| container_volume |
12 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Feizabadi, Mitra Shojania |
| doi_str_mv |
10.1186/1742-4682-12-3 |
| title_sort |
modeling drug resistance in a conjoint normal-tumor setting |
| title_auth |
Modeling drug resistance in a conjoint normal-tumor setting |
| abstract |
Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 |
| abstractGer |
Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 |
| abstract_unstemmed |
Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies. © Shojania Feizabadi and Witten; licensee BioMed Central. 2015 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_2027 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Modeling drug resistance in a conjoint normal-tumor setting |
| url |
https://dx.doi.org/10.1186/1742-4682-12-3 |
| remote_bool |
true |
| author2 |
Witten, Tarynn M |
| author2Str |
Witten, Tarynn M |
| ppnlink |
39178482X |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/1742-4682-12-3 |
| up_date |
2024-07-03T23:37:56.938Z |
| _version_ |
1803603019760140289 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029130530</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519175431.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1742-4682-12-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029130530</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1742-4682-12-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Feizabadi, Mitra Shojania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Modeling drug resistance in a conjoint normal-tumor setting</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Shojania Feizabadi and Witten; licensee BioMed Central. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background In this paper, we modify our previously developed conjoint tumor-normal cell model in order to make a distinction between tumor cells that are responsive to chemotherapy and those that may show resistance. Results Using this newly developed core model, the evolution of three cell types: normal, tumor, and drug-resistant tumor cells, is studied through a series of numerical simulations. In addition, we illustrate critical factors that cause different dynamical patterns for normal and tumor cells. Among these factors are the co-dependency of the normal and tumor cells, the cells’ response mechanism to a single or multiple chemotherapeutic treatment, the drug administration sequence, and the treatment starting time. Conclusion The results provide us with a deeper understanding of the possible evolution of normal, drug-responsive, and drug-resistant tumor cells during the cancer progression, which may contribute to improving the therapeutic strategies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer modeling</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cellular aging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Conjoint cell growth</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug resistance</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witten, Tarynn M</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Theoretical biology and medical modelling</subfield><subfield code="d">London : BioMed Central, 2004</subfield><subfield code="g">12(2015), 1 vom: 15. Jan.</subfield><subfield code="w">(DE-627)39178482X</subfield><subfield code="w">(DE-600)2156462-0</subfield><subfield code="x">1742-4682</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:01</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1742-4682-12-3</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">01</subfield></datafield></record></collection>
|
| score |
7.4000998 |